Drug reference

psilocybin

Psychedelic · Investigational (Antidepressant, Substance use disorder treatment, Migraine treatment, OCD treatment, Anti-inflammatory)

PsychedelicInvestigational (Antidepressant, Substance use disorder treatment, Migraine treatment, OCD treatment, Anti-inflammatory)

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Primary effects mediated by activation of 5HT2A receptors. Produces profound hallucinations. Efficacy in preclinical models as an anti-inflammatory.

Indications

Depression (in clinical trials)Substance use disorder (in clinical trials)Migraine (in clinical trials)Obsessive-compulsive disorder (in clinical trials)

Side effects

Serious

Unintentional, potentially fatal poisoning (due to misidentification of poisonous mushrooms)

Related guidelines

Substance use disorders

NIMHANS · Psychiatry · 2022

Depression in adults

IPS · Psychiatry · 2023

Alcohol use disorder

MOHFW · Psychiatry · 2021

Migraine — preventive therapy

AAN · Neurology · 2015

Hypertensive disorders of pregnancy

FOGSI · Obstetrics & Gynaecology · 2019

Other Psychedelic drugs

mescaline

0 brands

Ask House about psilocybin

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team